IL15 and leukemia: The American National Cancer Institute has identified IL-15 as one of the most promising immunotherapy targets for cancer [40] and the anti-tumour response of IL-15 has been well documented in experimental systems and in clinical cancer studies, notably in cutaneous T-cell lymphoma, leukemia of large granular lymphocytes and multiple myeloma [39].